Literature DB >> 23255310

Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.

Banu Aygun1, Nicole A Mortier, Matthew P Smeltzer, Barry L Shulkin, Jane S Hankins, Russell E Ware.   

Abstract

Glomerular hyperfiltration and microalbuminuria/proteinuria are early manifestations of sickle nephropathy. The effects of hydroxyurea therapy on these renal manifestations of sickle cell anemia (SCA) are not well defined. Our objective was to investigate the effects of hydroxyurea on glomerular filtration rate (GFR) measured by (99m)Tc-DTPA clearance, and on microalbuminuria/proteinuria in children with SCA. Hydroxyurea study of long-term effects (HUSTLE) is a prospective study (NCT00305175) with the goal of describing the long-term cellular, molecular, and clinical effects of hydroxyurea therapy in SCA. Glomerular filtration rate, urine microalbumin, and serum cystatin C were measured before initiating hydroxyurea therapy and then repeated after 3 years. Baseline and Year 3 values for HUSTLE subjects were compared using the Wilcoxon Signed Rank test. Associations between continuous variables were evaluated using Spearman correlation coefficient. Twenty-three children with SCA (median age 7.5 years, range, 2.5-14.0 years) received hydroxyurea at maximum tolerated dose (MTD, 24.4 ± 4.5 mg/kg/day, range, 15.3-30.6 mg/kg/day). After 3 years of treatment, GFR measured by (99m)Tc-DTPA decreased significantly from 167 ± 46 mL/min/1.73 m² to 145 ± 27 mL/min/1.73 m² (P = 0.016). This decrease in GFR was significantly associated with increase in fetal hemoglobin (P = 0.042) and decrease in lactate dehydrogenase levels (P = 0.035). Urine microalbumin and cystatin C levels did not change significantly. Hydroxyurea at MTD is associated with a decrease in hyperfiltration in young children with SCA.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23255310      PMCID: PMC4673980          DOI: 10.1002/ajh.23365

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  25 in total

1.  Early glomerular dysfunction in patients with sickle cell anemia.

Authors:  F Schmitt; F Martinez; G Brillet; I Giatras; G Choukroun; R Girot; D Bachir; F Galacteros; B Lacour; J P Grünfeld
Journal:  Am J Kidney Dis       Date:  1998-08       Impact factor: 8.860

2.  Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial.

Authors:  Russell E Ware; Renee C Rees; Sharada A Sarnaik; Rathi V Iyer; Ofelia A Alvarez; James F Casella; Barry L Shulkin; Eglal Shalaby-Rana; C Frederic Strife; John H Miller; Peter A Lane; Winfred C Wang; Scott T Miller
Journal:  J Pediatr       Date:  2010-01       Impact factor: 4.406

3.  Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature.

Authors:  Jean-Philippe Haymann; Katia Stankovic; Pierre Levy; Virginie Avellino; Pierre-Louis Tharaux; Emmanuel Letavernier; Gilles Grateau; Laurent Baud; Robert Girot; François Lionnet
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 8.237

4.  Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.

Authors:  T R Kinney; R W Helms; E E O'Branski; K Ohene-Frempong; W Wang; C Daeschner; E Vichinsky; R Redding-Lallinger; B Gee; O S Platt; R E Ware
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

5.  Prevalence, prevention, and treatment of microalbuminuria and proteinuria in children with sickle cell disease.

Authors:  Kathleen T McKie; Coral D Hanevold; Caterina Hernandez; Jennifer L Waller; Luis Ortiz; Kathleen M McKie
Journal:  J Pediatr Hematol Oncol       Date:  2007-03       Impact factor: 1.289

6.  Early blood transfusions protect against microalbuminuria in children with sickle cell disease.

Authors:  Ofelia Alvarez; Brenda Montane; Gabriela Lopez; James Wilkinson; Tracie Miller
Journal:  Pediatr Blood Cancer       Date:  2006-07       Impact factor: 3.167

Review 7.  Hydroxyurea for children with sickle cell disease.

Authors:  Matthew M Heeney; Russell E Ware
Journal:  Pediatr Clin North Am       Date:  2008-04       Impact factor: 3.278

Review 8.  Sickle cell disease and the kidney.

Authors:  Jon I Scheinman
Journal:  Nat Clin Pract Nephrol       Date:  2008-12-02

9.  A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia.

Authors:  Courtney D Thornburg; Natalia Dixon; Shelly Burgett; Nicole A Mortier; William H Schultz; Sherri A Zimmerman; Melanie Bonner; Kristina K Hardy; Agustin Calatroni; Russell E Ware
Journal:  Pediatr Blood Cancer       Date:  2009-05       Impact factor: 3.167

10.  Revisiting normal (51)Cr-ethylenediaminetetraacetic acid clearance values in children.

Authors:  A Piepsz; M Tondeur; H Ham
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-25       Impact factor: 10.057

View more
  35 in total

Review 1.  Sickle cell disease: renal manifestations and mechanisms.

Authors:  Karl A Nath; Robert P Hebbel
Journal:  Nat Rev Nephrol       Date:  2015-02-10       Impact factor: 28.314

Review 2.  2015 Clinical trials update in sickle cell anemia.

Authors:  Natasha Archer; Frédéric Galacteros; Carlo Brugnara
Journal:  Am J Hematol       Date:  2015-10       Impact factor: 10.047

3.  Interventions for chronic kidney disease in people with sickle cell disease.

Authors:  Noemi Ba Roy; Patricia M Fortin; Katherine R Bull; Carolyn Doree; Marialena Trivella; Sally Hopewell; Lise J Estcourt
Journal:  Cochrane Database Syst Rev       Date:  2016-10

Review 4.  Update on the use of hydroxyurea therapy in sickle cell disease.

Authors:  Trisha E Wong; Amanda M Brandow; Wendy Lim; Richard Lottenberg
Journal:  Blood       Date:  2014-10-06       Impact factor: 22.113

5.  A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.

Authors:  Jeremie H Estepp; Matthew P Smeltzer; Guolian Kang; Chen Li; Winfred C Wang; Christina Abrams; Banu Aygun; Russell E Ware; Kerri Nottage; Jane S Hankins
Journal:  Am J Hematol       Date:  2017-09-28       Impact factor: 10.047

Review 6.  Systematic and Meta-Analytic Review: Medication Adherence Among Pediatric Patients With Sickle Cell Disease.

Authors:  Kristin Loiselle; Jennifer L Lee; Lauren Szulczewski; Sarah Drake; Lori E Crosby; Ahna L H Pai
Journal:  J Pediatr Psychol       Date:  2015-09-18

7.  Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study.

Authors:  Omar Niss; Adam Lane; Monika R Asnani; Marianne E Yee; Ashok Raj; Susan Creary; Courtney Fitzhugh; Prasad Bodas; Santosh L Saraf; Sharada Sarnaik; Prasad Devarajan; Punam Malik
Journal:  Blood Adv       Date:  2020-04-14

8.  Hydroxyurea prevents onset and progression of albuminuria in children with sickle cell anemia.

Authors:  Rima S Zahr; Jane S Hankins; Guolian Kang; Chen Li; Winfred C Wang; Jeffrey Lebensburger; Jeremie H Estepp
Journal:  Am J Hematol       Date:  2018-11-29       Impact factor: 10.047

9.  Proteinuria in adults with sickle-cell disease: the role of hydroxycarbamide(hydroxyurea) as a protective agent.

Authors:  Geraldo B Silva Junior; Ana Patrícia F Vieira; Amanda X Couto Bem; Marília P Alves; Gdayllon C Meneses; Alice M C Martins; Sonia M H A Araújo; Alexandre V Libório; Elizabeth F Daher
Journal:  Int J Clin Pharm       Date:  2014-06-17

10.  Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.

Authors:  Min Dong; Patrick T McGann; Tomoyuki Mizuno; Russell E Ware; Alexander A Vinks
Journal:  Br J Clin Pharmacol       Date:  2016-02-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.